

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 22, 2024

---

**MINERALYS THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of incorporation  
or organization)

**001-41614**  
(Commission File Number)

**84-1966887**  
(I.R.S. Employer Identification No.)

**150 N. Radnor Chester Road, Suite F200**  
**Radnor, Pennsylvania 19087**  
(Address of principal executive offices) (Zip Code)

**(888) 378-6240**  
(Registrant's telephone number, include area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
<b>Common Stock, par value \$0.0001 per share</b>	<b>MLYS</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On May 22, 2024, Mineralys Therapeutics, Inc. (the Company) held its 2024 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown:

Proposal 1 – To elect one director to serve as a Class I director for a three-year term to expire at the 2027 annual meeting of stockholders.

Name	For	Withhold	Broker Non-Votes
Jon Congleton	26,418,385	3,775,533	1,838,014

Proposal 2 – To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

For	Against	Abstain	Broker Non-Votes
32,025,366	1,187	5,379	0

Both Proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company’s common stock.

Each Proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 9, 2024.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 22, 2024

**MINERALYS THERAPEUTICS, INC.**

By: /s/ Adam Levy

Name: Adam Levy

Title: Chief Financial Officer and Secretary